<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02162979</url>
  </required_header>
  <id_info>
    <org_study_id>52031</org_study_id>
    <nct_id>NCT02162979</nct_id>
  </id_info>
  <brief_title>Sildenafil (Viagra) for the Treatment of Dyskinesias in Parkinson's Disease</brief_title>
  <official_title>A Double-Blind, Placebo-Controlled, Cross-Over Study of Sildenafil (Viagra) for the Treatment of Dyskinesias in Parkinson's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Loma Linda University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Loma Linda University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to determine if Viagra is effective in reducing dyskinesias in patients with
      Parkinson's Disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Inclusion Criteria:

        1. Diagnosis of idiopathic Parkinson's disease.

        2. Age &gt; 40 years.

        3. willingness and ability to comply with the study requirements and give informed consent.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Not enough subjects.
  </why_stopped>
  <start_date>February 2002</start_date>
  <completion_date type="Actual">January 2009</completion_date>
  <primary_completion_date type="Actual">January 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Duration of Dyskinesia.</measure>
    <time_frame>2 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent Change in &quot;on&quot; Time</measure>
    <time_frame>4 weeks</time_frame>
    <description>&quot;on&quot; time is the period in which the subject is symptom free. We will track the amount of time the subject is considered symptom free before and after treatment. This value will be represented as a percent change.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Dose of Anti-parkinsonian Medications</measure>
    <time_frame>7 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Parkinson's Disease</condition>
  <arm_group>
    <arm_group_label>Viagra</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>subjects will be randomized to active treatment for 2 weeks, washout for 1 week, then enter the other study arm for two weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo comparator</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>subjects will be randomized to placebo treatment for 2 weeks, washout for 1 week, then enter the other study arm for two weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sildenafil</intervention_name>
    <description>sildenafil 50mg BID for 2 weeks</description>
    <arm_group_label>Viagra</arm_group_label>
    <other_name>Viagra</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo comparator</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diagnosis of idiopathic Parkinson's disease, Hoehn and Yahr stage 2.0 to 4.0.

          2. Presence of drug-induced dyskinesias

          3. Age&gt;40 years.

          4. Willingness and ability to comply with the study requirements and give informed
             consent.

        Exclusion Criteria:

          1. Atypical parkinsonian syndrome due to drugs, metabolic disorders, encephalitis, or
             degenerative diseases.

          2. History of stereotaxic brain surgery.

          3. Clinical history of dementia.

          4. Known major psychiatric disorder, major depression, schizophrenia. Known alcoholism or
             substance dependence within previous 12 months.

          5. History of major hematological, renal, or hepatic abnormalities.

          6. Known coronary artery disease including angina or myocardial infarction within the
             last 6 months. Significant cardiovascular disease including cardiac failure, unstable
             angina or life-threatening arrhythmia within the last 6 months.

          7. History of stroke within the last 6 months.

          8. Abnormal EKG consistent with cardiac ischemia.

          9. Treatment with nitrates. Nitrates or any NO donors in any dosage form (oral,
             sublingual, transdermal, inhalation, or aerosols).

         10. Malignant hypertension or SBP . 180 or &lt;90, or DBP .110 or &lt;50.

         11. History of priapism.

         12. Known history of retinitis pigmentosa.

         13. Positive pregnancy test.

         14. History of bleeding disorder.

         15. Patients with active peptic ulcer disease associated with bleeding.

         16. Unwillingness to use adequate contraceptive methods if of childbearing potential.

         17. Patients with medical or psychological condition or social circumstances that would
             impair their ability to participate in the study.

         18. Use of Viagra or any experimental drugs within 30 days of screening visit.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David M. Swope, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Loma Linda University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Loma Linda University</name>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <zip>92354</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 26, 2007</study_first_submitted>
  <study_first_submitted_qc>June 12, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 13, 2014</study_first_posted>
  <results_first_submitted>June 20, 2014</results_first_submitted>
  <results_first_submitted_qc>June 20, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 22, 2014</results_first_posted>
  <last_update_submitted>March 5, 2018</last_update_submitted>
  <last_update_submitted_qc>March 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Parkinson's disease</keyword>
  <keyword>PD</keyword>
  <keyword>dyskinesia</keyword>
  <keyword>treatment</keyword>
  <keyword>motor complications</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Dyskinesias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sildenafil Citrate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Documentation regarding the randomization of the two enrolled participants cannot be located. Therefore no meaningful data are available for entry in the data tables.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Viagra</title>
          <description>subjects will be randomized to active treatment for 2 weeks, washout for 1 week, then enter the other study arm for two weeks.
sildenafil: sildenafil 50mg BID for 2 weeks</description>
        </group>
        <group group_id="P2">
          <title>Placebo Comparator</title>
          <description>subjects will be randomized to placebo treatment for 2 weeks, washout for 1 week, then enter the other study arm for two weeks.
Placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Viagra</title>
          <description>subjects will be randomized to active treatment for 2 weeks, washout for 1 week, then enter the other study arm for two weeks.
sildenafil: sildenafil 50mg BID for 2 weeks</description>
        </group>
        <group group_id="B2">
          <title>Placebo Comparator</title>
          <description>subjects will be randomized to placebo treatment for 2 weeks, washout for 1 week, then enter the other study arm for two weeks.
Placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="0"/>
            <count group_id="B2" value="0"/>
            <count group_id="B3" value="0"/>
          </count_list>
        </analyzed>
      </analyzed_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Duration of Dyskinesia.</title>
        <time_frame>2 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Viagra</title>
            <description>subjects will be randomized to active treatment for 2 weeks, washout for 1 week, then enter the other study arm for two weeks.
sildenafil: sildenafil 50mg BID for 2 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo Comparator</title>
            <description>subjects will be randomized to placebo treatment for 2 weeks, washout for 1 week, then enter the other study arm for two weeks.
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Duration of Dyskinesia.</title>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in &quot;on&quot; Time</title>
        <description>&quot;on&quot; time is the period in which the subject is symptom free. We will track the amount of time the subject is considered symptom free before and after treatment. This value will be represented as a percent change.</description>
        <time_frame>4 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Viagra</title>
            <description>subjects will be randomized to active treatment for 2 weeks, washout for 1 week, then enter the other study arm for two weeks.
sildenafil: sildenafil 50mg BID for 2 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo Comparator</title>
            <description>subjects will be randomized to placebo treatment for 2 weeks, washout for 1 week, then enter the other study arm for two weeks.
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in &quot;on&quot; Time</title>
          <description>&quot;on&quot; time is the period in which the subject is symptom free. We will track the amount of time the subject is considered symptom free before and after treatment. This value will be represented as a percent change.</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Dose of Anti-parkinsonian Medications</title>
        <time_frame>7 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Viagra</title>
            <description>subjects will be randomized to active treatment for 2 weeks, washout for 1 week, then enter the other study arm for two weeks.
sildenafil: sildenafil 50mg BID for 2 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo Comparator</title>
            <description>subjects will be randomized to placebo treatment for 2 weeks, washout for 1 week, then enter the other study arm for two weeks.
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Dose of Anti-parkinsonian Medications</title>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Viagra</title>
          <description>subjects will be randomized to active treatment for 2 weeks, washout for 1 week, then enter the other study arm for two weeks.
sildenafil: sildenafil 50mg BID for 2 weeks</description>
        </group>
        <group group_id="E2">
          <title>Placebo Comparator</title>
          <description>subjects will be randomized to placebo treatment for 2 weeks, washout for 1 week, then enter the other study arm for two weeks.
Placebo</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Tonya Hamilton, reszearch Compliance Auditor</name_or_title>
      <organization>Loma Linda University</organization>
      <phone>909-558-4908</phone>
      <email>thamilton@llu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

